Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Extension Study of Ralinepag in Pulmonary Arterial Hypertension
2018-001189-40Phase 3Active
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by Arena Pharmaceuticals, Inc. Started Nov 2018; status: active.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2018-001189-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001189-40.